modelP01BF07

Extends from Pharmacokinetic.Models.PK_2C_enteral.

Information

name:ArtemisininAndPiperaquine
ATC code:P01BF07
route:oral
compartments:2
dosage:320mg
volume of distribution:243L
clearance:1.22L/h
other parameters in model implementation

Artemisinin and piperaquine is a fixed-dose artemisinin-based combination therapy (ACT) used primarily for the treatment of uncomplicated Plasmodium falciparum malaria. Artemisinin acts rapidly to reduce parasite burden, while piperaquine provides a longer duration of action to clear remaining parasites. This combination is approved and widely used as a first-line therapy in several malaria-endemic countries.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adults, both sexes, after oral administration of fixed-dose combination tablets.

References

  1. Reuter, SE, et al., & Pace, S (2015). Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin. Clinical drug investigation 35(9) 559–567. DOI:10.1007/s40261-015-0312-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26293519

  2. Tarning, J, et al., & Lindegardh, N (2012). Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clinical pharmacology and therapeutics 91(3) 497–505. DOI:10.1038/clpt.2011.254 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22258469

  3. Tarning, J, et al., & Lindegardh, N (2012). Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrobial agents and chemotherapy 56(4) 1997–2007. DOI:10.1128/AAC.05756-11 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22252822

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)